139 related articles for article (PubMed ID: 20721791)
21. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of randomised controlled trials with adaptive and traditional group sequential designs - applications in cardiovascular clinical trials.
Zhang J; Saju C
BMC Med Res Methodol; 2023 Sep; 23(1):200. PubMed ID: 37679710
[TBL] [Abstract][Full Text] [Related]
23. Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.
Ibrahim JG; Chen MH; Xia HA; Liu T
Biometrics; 2012 Jun; 68(2):578-86. PubMed ID: 21955084
[TBL] [Abstract][Full Text] [Related]
24. Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity.
Liu F; Walters SJ; Julious SA
BMC Med Res Methodol; 2017 Oct; 17(1):149. PubMed ID: 28969588
[TBL] [Abstract][Full Text] [Related]
25. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
26. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes.
Lin R; Thall PF; Yuan Y
Biometrics; 2020 Mar; 76(1):304-315. PubMed ID: 31273750
[TBL] [Abstract][Full Text] [Related]
27. Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.
Chen MH; Ibrahim JG; Amy Xia H; Liu T; Hennessey V
Stat Med; 2014 Apr; 33(9):1600-18. PubMed ID: 24343859
[TBL] [Abstract][Full Text] [Related]
28. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
Lin R; Yin G
Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
[TBL] [Abstract][Full Text] [Related]
29. Bayesian indirect and mixed treatment comparisons across longitudinal time points.
Ding Y; Fu H
Stat Med; 2013 Jul; 32(15):2613-28. PubMed ID: 23229717
[TBL] [Abstract][Full Text] [Related]
30. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
Wang Y; Travis J; Gajewski B
BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
[TBL] [Abstract][Full Text] [Related]
31. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
Yan D; Wages NA; Dressler EV
J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
[TBL] [Abstract][Full Text] [Related]
32. The Add-Arm Design for Unimodal Response Curve with Unknown Mode.
Chang M; Wang J
J Biopharm Stat; 2015; 25(5):1039-64. PubMed ID: 25331003
[TBL] [Abstract][Full Text] [Related]
33. An adaptive design for phase II non-oncology dose selection clinical trials.
Su Z
Clin Drug Investig; 2010; 30(6):397-403. PubMed ID: 20373828
[TBL] [Abstract][Full Text] [Related]
34. A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.
Sambucini V
Stat Med; 2010 Jun; 29(13):1430-42. PubMed ID: 20099246
[TBL] [Abstract][Full Text] [Related]
35. A Bayesian response-adaptive dose-finding and comparative effectiveness trial.
Heath A; Yaskina M; Pechlivanoglou P; Rios D; Offringa M; Klassen TP; Poonai N; Pullenayegum E
Clin Trials; 2021 Feb; 18(1):61-70. PubMed ID: 33231105
[TBL] [Abstract][Full Text] [Related]
36. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
Zhou Y; Lee JJ; Yuan Y
Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
[TBL] [Abstract][Full Text] [Related]
37. Optimizing interim analysis timing for Bayesian adaptive commensurate designs.
Wu X; Xu Y; Carlin BP
Stat Med; 2020 Feb; 39(4):424-437. PubMed ID: 31799737
[TBL] [Abstract][Full Text] [Related]
38. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
39. One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint.
Whitehead J; Jaki T
Stat Med; 2009 Feb; 28(5):828-47. PubMed ID: 19061203
[TBL] [Abstract][Full Text] [Related]
40. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
